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Background
Real clinical setting data about onabotulinumtoxinA treat-
ment on chronic migraine are poor, especially in patients
with medication-overuse headache (MOH) and ≥ 65 years
old, as well as data on predictors of responsivity. W pre-
sent results on chronic migraine patients treated at the
Padua Headache Centre from April 2014 to March 2015.
Materials and methods
By compiling a headache diary, efficacy parameters
(mean reduction of headache days and hours) were eval-
uated at 90 days after the first cycle. We analyzed also:
30% and 50% response rates and the percent of first-
time responders to II cycle; association with headache
related symptoms and comorbidities (depression/anxiety
disorders, hypertension, sleep disturbances, caffeine
intake, BMI >30).
Results
Forty patients were evaluated (35 F, 5 M; mean age,
53±12.8) of which 37/40 (93%) with MOH. At 90 days after
the first cycle headache diary documented a significant
mean reduction of headache days (56.2 vs 69.2, p < 0.005),
of the total hours of headache (455.4 vs 601.6, p <0.005), of
the hours of moderate pain (147.8 vs 263.5, p < 0.005) and
severe pain (102.5 vs 131.2, p < 0.05), of the consumption
of triptans (30.7 vs 46.5, p < 0.001) and associations (15.4 vs
22.7, p <0.05). The 8 patients ≥65 years old did not present
a significant reduction of efficacy parameters vs younger
patients. 50% and 30% response rate was respectively 22.5%
and 38% for at least one efficacy parameter, 15% and 25%
for headache days, of 20% and 35% for hours, 12.5 and 23%
for both parameters. Percent of “first-time 50% responders”
was 15.8% and 10.8% respectively for headache days and
hours; percent of “first-time 30% responders” was 26.3%
and 15.8%. Cluster analysis showed a higher severe head-
ache share and a lower share of mild headache in respon-
sive patients vs non responsive: 146.7 (26.3%) vs 119.1
(17.6%) severe pain hours, 162.2 (29.1%) vs 287.1 (41.1%)
mild pain hours. ANOVA analysis did not show significant
association between responsivity and headache symptoms
or related comorbidities, except for a lower response trend
of depression/anxiety at limit of significance (p = 0.07).
Conclusions
OnabotulinumtoxinA treatment appears useful also in a
clinical setting with high presence of MOH. Responsive
patients are <65 years old and have a higher frequency
of severe headache and a lower share of mild headache.
Depression/anxiety disorders are associated also to a
lower responsiveness trend at limit of significance.
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